Deaths / year
13,000
GBD (indicative unless refreshed)
DALYs / year
1,600,000
GBD
Pathogen
Helminth
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic hepatic/urogenital fibrosis; bladder cancer risk; female genital schistosomiasis
Classification
Chronic disease
Onset
chronic
Persistent-symptom %
not quantified as a single figure (see notes)
Source: Colley 2014 Lancet
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Snail control & safe water access | Vector control | Approved | Reduce Bulinus / Biomphalaria intermediate hosts | WHO schistosomiasis |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Praziquantel | Anthelmintic | Approved | Broad schistosomicide; MDA backbone | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Oxamniquine | Anthelmintic | Approved | S. mansoni (limited use) | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Chronic fibrosis & bladder cancer surveillance | Oncology follow-up | Approved | Hepatic/urogenital sequelae | Colley 2014 Lancet |
Associated drug targets (Open Targets): IL4R, IL13, SPP1, IL33, KIT, HMGB1
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0015254 · Updated 2026-07-10. Associations, not a diagnostic test.